Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
emnergize: Empasiprubart in Adults With CIDP
NCT07091630Phase 3Recruiting
- Sponsor
- argenx
- Start
- Sep 2025
- Primary completion
- Oct 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 25
01
Overview
A Phase 3 trial of empasiprubart in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by argenx. Started Sep 2025; status: recruiting.
02
Drugs
empasiprubart
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NCT07091630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07091630.